Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Hoffmann-La Roche
Eisai Inc.
Olivia Newton-John Cancer Research Institute
Advanced Accelerator Applications
Jonsson Comprehensive Cancer Center
Advanced Accelerator Applications
University of Washington
Imperial College London
M.D. Anderson Cancer Center
Advanced Accelerator Applications
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
University of Iowa
University Health Network, Toronto
University of Alberta
Camurus AB
Crinetics Pharmaceuticals Inc.
Amgen
Advanced Accelerator Applications
Merck Sharp & Dohme LLC
ITM Solucin GmbH
University of California, San Francisco
Case Comprehensive Cancer Center
University of Iowa
British Columbia Cancer Agency
Orano Med LLC
ITM Solucin GmbH
Instituto do Cancer do Estado de São Paulo
Abramson Cancer Center at Penn Medicine
Memorial Sloan Kettering Cancer Center
Harbour BioMed (Guangzhou) Co. Ltd.
Melanoma and Skin Cancer Trials Limited
University Health Network, Toronto